Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Diabetes Obes MetabJul 26, 2026 (epub)
Luca Busetto, Cynthia Osorto Contreras, Mikkel Hovden Christensen et al.
✦ AI-curated · Sources linked
In 30 seconds
This secondary analysis of the phase 3a REDEFINE 1 trial evaluated the efficacy of CagriSema in achieving anthropometric targets and cardiometabolic outcomes in adults with obesity. The study found that 30.3% of participants receiving CagriSema achieved both BMI <27 kg/m² and WHtR <0.53 at week 68, compared to lower rates in other treatment groups.
Key findings
- 30.3% of CagriSema participants achieved BMI <27 kg/m² and WHtR <0.53 at week 68.
- 19.1%, 9.0%, and 3.3% of participants achieved the same targets with semaglutide, cagrilintide, and placebo, respectively.
- Anthropometric targets were better indicators of cardiometabolic outcomes than percentage weight loss at stringent cut-off values.
Why it matters
The study highlights the importance of achieving specific anthropometric targets in obesity management, suggesting that these targets may be more effective than percentage weight loss in improving cardiometabolic health.